Thoughts on Kite’s Licensing Agreement with Refuge Biotechnologies
On Thursday, October 20, Gilead (Kite) announced (press release) that it has entered into a WW license agreement with Refuge Biotechnologies. Of note, Kite will have exclusive rights to utilize Refuge’s proprietary gene expression platform for the development of CAR-Ts in blood cancers. Below, Celltelligence provides insights on Refuge’s synthetic biology technology, while discussing Gilead’s licensing strategy.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.